单纯促性腺激素释放激素类似物或联合重组人生长激素治疗青春期矮小患儿的疗效分析  

Efficacy of treatment with gonadotropin-releasing hormone analogue alone or combined with recombinant human growth hormone in pubertal short children

作　　者：滕月春[1] 王伟[1] 董治亚[1] 王瑞芳[1] 倪继红[1] 孙文鑫[1] 陈凤生[1] 王德芬[1] 

机构地区：[1]上海交通大学医学院附属瑞金医院儿内科,200025

出　　处：《中华内分泌代谢杂志》2011年第4期292-295,共4页Chinese Journal of Endocrinology and Metabolism

摘　　要：目的 比较分析单纯促性腺激素释放激素类似物（GnRHa）或联合重组人生长激素（rhGH）治疗青春期非生长激素缺乏矮小（NGHDSS）患儿的助长疗效,探讨科学有效的青春期助长治疗方案.方法 42例青春期NGHDSS患儿（男性14,女性28）,采用GnRHa联合rhGH治疗者（联合组）30例,单独GnRHa 治疗者（单治组）12例.GnRHa初始剂量100ug·kg-1·d-1（28 d）,维持剂量60-80μg·kg-1·d-1（28d）;rhGH初始剂量0.15 IU·ks-1·d-1（28 d）,维持剂量0.10～0.15 IU·ks-1·d-1（28 d）,疗程均为1-2年.主要观察各组年生长速率（GV）、对年龄的身高标准差分值（HtSDSCA）、对骨龄的身高标准差分值（HtSDSBA）、预测身高标准差分值（PAHSDS）的动态变化.结果 （1）1年疗效：联合组治疗前后比较,GV、HtSDSCA、HtSDSBA、PAHSDS变化均有统计学意义（均P〈0.05）.单治组患儿治疗前后比较,GV、HtSDSCA、HtSDSBA、PAHSDS变化均无统计学意义（均P〉0.05）.2组间比较,GV、HtSDSBA、PAHSDS均有显著性差异（均P〈0.05）.（2）2年疗效：联合组治疗前后比较,GV、HtSDSCA、HtSDSBA、PAHSDS变化均有统计学意义（均P〈0.05）.单治组治疗前后比较,GV、HtSDSCA、HtSDSBA、PAHSDS变化均无统计学意义（均P〉0.05）.2组间比较,GV、HtSDSBA、HtSDSCA、PAHSDS均有显著性差异（均P〈0.05）.结论 采用GnRHa联合rhGH治疗青春发育初期的NGHDSS患儿能有效促进近期生长速率,其疗效明显优于单独GnRHa治疗,但对成年终身的贡献尚待研究.Objective To assess the efficacy of gonadotropin-releasing hormone analogue（GnRHa）with or without recombinant human growth hormone（rhGH）treatment in Chinese short pubertal children with non-growth hormone deficiency.Methods Of 42 short pubertal children（14 males,28 females）without growth hormone deftcieney,the average age was（11.6±0.8）year.30 children were treated with slow release GnRHa with initial dose （100μg·kg-1·d-1,28d）and maintenance dose（60-80μg·kg-1·d-1,28d）labd rgGH with initial dose（0.15IU·kg-1·d-1）and maintenance dose（0.10-0.15IU·kg-1·d-1）for at least 1year.16 of them were still ongoing till the end of the second year.12 children were treated with GnRHa alone by initial dose（100μg·kg-1·d-1,28d）and maintenance dose （60-80μg·kg-1·d-1,28d）,and 7 of them remained on it for 2 years.Dynamic changes including annual growth velocity（GV）,bone age（BA）/chronologic age（CA）ratio,Tanner stage,height SDS for CA （HtSDSCA）,height SDS for BA（HtSDSBA）,and predicted adult height （PAHSDS）were observed.Results By the end of the first year tretment with combination therapy,the following parameters：GV,HtSDSCA,HtSDSBA,and PAHSDS all increased significantly（all P〈0.05）.Treatment with GnRHa alone did not yield significant changes in GV,HtSDSCA,HtSDSBA,and PAHSDS（all P〉0.05）.Changes in GV,HtSDSBA,and PAHSDS between these two groups were statistically significant（all P〈0.05）.By the end of the second year treatment,in the combination group,GV slowed from 6.7 to 5.5 cm/year（P〈0.05）.HtSDSCA,HtSDSBA,PAHSDS increased（all P〈0.05）.In the group with GnRHa treatment alone,GV slowed from 4.0 to 3.6 cm/year（P〉0.05）.HtSDSCA,HtSDSBA,PAHSDS increased（all P〉0.05）.Changes in GV,HtSDSCA,HtSDSBA,and PAHSDS between these 2 groups were statistically significant respectively（all P〈0.05）.Conclusion This combined treatment regimen significantly impreved the growth by increasing growth rate and delaying bone matumtion in pub

关 键 词：特发性矮小 促性腺激素释放激素类似物 重组人生长激素 

分 类 号：R725.8[医药卫生—儿科]